Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rommer

Showing results (11-20 of 255) with videos related to

Pageof 26
Sort By:
Current Pharmaceutical Design|September 21, 2021
Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum DisordersPaulus Rommer, Uwe K Zettl
Wiener Medizinische Wochenschrift (1946)|December 6, 2022
Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesisMarkus Ponleitner, Paulus Stefan Rommer
Vaccines|February 2, 2021
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting TherapiesJohann Sellner, Paulus S Rommer
Current Pharmaceutical Design|June 27, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part II: Autoimmunity Beyond the CNS and Other DisordersPaulus S Rommer, Uwe K Zettl
Expert Opinion on Pharmacotherapy|March 13, 2018
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patientsPaulus S Rommer, Uwe K Zettl
Nature Reviews. Neurology|July 26, 2023
New consensus guidelines on vaccination in multiple sclerosisUwe K Zettl, Paulus S Rommer
Current Pharmaceutical Design|April 5, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNSPaulus S Rommer, Uwe K Zettl
The Lancet. Neurology|May 21, 2018
Applying the 2017 McDonald diagnostic criteria for multiple sclerosisPaulus S Rommer, Uwe K Zettl
Journal of Inherited Metabolic Disease|May 6, 2025
Blood Biomarkers Reflecting Brain Pathology-From Common Grounds to Rare FrontiersIsabelle Weinhofer, Paulus Rommer, Johannes Berger
Immunology|February 1, 1974
Response of lymphocytes to plant lectins. I. A thymic-dependent lymphoid population responsive to pokeweed mitogenM E Weksler, S Bodine, J Rommer
Pageof 26

Showing results (11-20 of 255) with videos related to

Sort By:
Pageof 26
Current Pharmaceutical Design|September 21, 2021
Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum DisordersPaulus Rommer, Uwe K Zettl
Wiener Medizinische Wochenschrift (1946)|December 6, 2022
Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesisMarkus Ponleitner, Paulus Stefan Rommer
Vaccines|February 2, 2021
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting TherapiesJohann Sellner, Paulus S Rommer
Current Pharmaceutical Design|June 27, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part II: Autoimmunity Beyond the CNS and Other DisordersPaulus S Rommer, Uwe K Zettl
Expert Opinion on Pharmacotherapy|March 13, 2018
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patientsPaulus S Rommer, Uwe K Zettl
Nature Reviews. Neurology|July 26, 2023
New consensus guidelines on vaccination in multiple sclerosisUwe K Zettl, Paulus S Rommer
Current Pharmaceutical Design|April 5, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNSPaulus S Rommer, Uwe K Zettl
The Lancet. Neurology|May 21, 2018
Applying the 2017 McDonald diagnostic criteria for multiple sclerosisPaulus S Rommer, Uwe K Zettl
Journal of Inherited Metabolic Disease|May 6, 2025
Blood Biomarkers Reflecting Brain Pathology-From Common Grounds to Rare FrontiersIsabelle Weinhofer, Paulus Rommer, Johannes Berger
Immunology|February 1, 1974
Response of lymphocytes to plant lectins. I. A thymic-dependent lymphoid population responsive to pokeweed mitogenM E Weksler, S Bodine, J Rommer
Pageof 26